AdipoLABs’ ‘REMISSION 1℃’ cancer treatment effect recognized internationally
2023 Malaysian Oncology Society Grand Prize Award… Proven effectiveness in cancer, pain relief, and immunotherapy
 ▲ Grand prize award ceremony in the paper poster category at the 34th Malaysian Oncology Society annual conference. 【Health News】 The cancer treatment effect of AdipoLABs’ ‘REMISSION 1℃’ has been recognized at overseas academic societies.
AdipoLABs Co., Ltd. (CEO Han Sung-ho) published a paper on the cancer treatment effects of its high-frequency hyperthermia cancer treatment device, 'REMISSION 1℃', at the Sabah International Convention Center in Malaysia from October 6 to 8. The device and the treatment won the grand prize at the 34th Malaysian Society of Oncology Annual Conference (ASCOMOS) held in ASCOMOS which is a high-quality academic conference held annually in Malaysia.
At this conference held with the participation of over 200 Malaysian oncology medical staff under the theme of ‘high-level expansion of oncology’, over 20 hospitals presented cancer treatment papers.
As a result of the review, Dr. Ho Gwo Fuang and Dr. Cheong E Von of UMMC (University Malaya Medical Centre) published a paper on treating cancer patients with ' REMISSION 1℃', a high-frequency hyperthermia cancer treatment device manufactured in Korea by AdipoLABs and their result was winning the grand prize.
Dr. Yvonne's thesis, 'Hyperthermia in the Treatment of Patients with Painful and Unresectable Abdominal or Pelvic Malignancies', points to increasing evidence that hyperthermia, used as an adjunct to standard oncology treatment, provides symptomatic improvement and tumor control. The board has evaluated the effects of hyperthermia on pain scores, quality of life, and immune response.
Hyperthermia, as an adjunct to standard oncology treatment, has proven to be beneficial in improving pain in patients with advanced malignancies. In addition, it has been noted that we cannot help but take into account that there may be a variety of factors, including social context that may affect overall quality of life.
Accordingly, although there was no significant improvement in quality of life, changes in immune response seemed promising and confirmed the role of hyperthermia in cancer immunotherapy.
|
Minister of Community Development and People's Welfare Datuk James Ratib, who attended the conference, said, “The first hyperthermia treatment in Sabah is a big step forward in creating better health and better hope for cancer patients.” “We congratulate this new frontier in the field of medicine for its promising healing outcomes.”
AdipoLABs used the high-frequency hyperthermia cancer treatment device REMISSION 1℃ for clinical purposes at the University Malaya Medical Center (UMMC), a Malaysian university hospital, in 2019.
Dr. Ho Gwo Fuang, Department of Oncology, UMMC, is a renowned cancer treatment specialist not only in Malaysia but also internationally.
So far, hospitals have treated about 200 cancer patients in Korea with the high-frequency hyperthermia cancer treatment device ' REMISSION 1℃', and through this academic conference, doctors have proven that REMISSION 1℃ is effective in cancer treatment, pain relief, and immunotherapy.
Han Sung-ho, CEO of AdipoLABs, said, “We hope that the results of this clinical trial will provide hope to countless cancer patients around the world.” He added, “The cancer treatment effect will continue in India, China, and other countries with the high-frequency cancer treatment device. We will promote the status of Korean medical devices to the world.”
Meanwhile, the equipment has been used not only at Seoul St. Mary's Hospital of the Catholic University of Korea but also at domestic general hospitals, oriental medicine hospitals, and nursing hospitals since AdipoLABs received manufacturing permission from the Ministry of Food and Drug Safety as a medical high-frequency heater to treat cancer in 2015. REMISSION 1℃ is a proven medical device that has shown consistent clinical effectiveness.
출처: [후생신보] 아디포랩스 ‘리미션1℃’ 암 치료효과 국제적 인정 (whosaeng.com)
